

Life Sciences: Toronto



Market Highlights

- Acorn, a biotechnology company based in Toronto, has raised \$8.1 million to enhance access to regenerative medicine through cell preservation.
- The Ontario government is investing \$40.0 million to support the growth and innovation of life sciences companies and biomanufacturers, enabling them to develop life-saving medicines and technologies and compete globally.


Sanofi celebrated the opening of its cutting-edge 200,000 square foot (sf) biomanufacturing facility, the largest of its kind in Canada, which will be dedicated to producing vaccines for whooping cough, diphtheria, and tetanus.

Major Developments Under Construction




606 Aberdeen Avenue

- SF: 280,000
- Chemistry and life sciences capabilities
- Delivery: Q2 2025
- Developer: McMaster University




44 Frid Street

- SF: 258,982
- Delivery: Q2 2025
- Developer: McMaster University



77 Wade Avenue

- SF: 155,000
- Delivery: Q4 2024
- Developer: Next Property Group



191 Longwood Road

- SF: 119,705
- Biomanufacturing hub for cell and gene therapy
- Delivery: Q3 2024
- Developer: McMaster University

Notable Leases



OmniaBio

190 Longwood Rd S
90,000 sf
Q4 2023



AtomVie

10 Aeropark Blvd
65,000 sf
Q4 2023



Element

2599 Speakman Dr
20,000 sf
Q4 2023



GlaxoSmithKline


100 Milverton Dr
24,327 sf
Q4 2023



Ipsen Biopharmaceuticals

5050 Satellite Dr
12,233 sf
Q4 2023

Life Sciences Related VC Funding



Companies	Deal Size	Deal Type
Acorn	\$8.1M	Series A
Mesosil	\$3.7M	Seed Round
HDAX Therapeutics	\$3.0M	Seed Round
IntelliStem	\$1.2M	Seed Round
ImmVue Therapeutics	\$683.4K	Later Stage VC